Active ingredients
Pharmacological Group
Used in the treatment of
- S06 Intracranial injury
- R63.0 Anorexia
- R62 Lack of expected normal physiological development
- R57.1 Hypovolaemic shock
- R53 Malaise and fatigue
- R07.2 Precordial pain
- P22 Respiratory distress of newborn
- P21 Birth asphyxia
- P15 Other birth injuries
- P07 Disorders related to short gestation and low birth weight, not elsewhere classified
- M34 Systemic sclerosis
- L94.0 Localized scleroderma [morphea]
- L93 Lupus erythematosus
- L40 Psoriasis
- L21 Seborrhoeic dermatitis
- L21.0 Seborrhoea capitis
- K86.1 Other chronic pancreatitis
- K76.9 Liver disease, unspecified
- K29.5 Chronic gastritis, unspecified
- K29.4 Chronic atrophic gastritis
- I42 Cardiomyopathy
- I25.2 Old myocardial infarction
- I25 Chronic ischaemic heart disease
- I21 Acute myocardial infarction
- I20 Angina pectoris
- G93.4 Encephalopathy, unspecified
- G72 Other myopathies
- F48.0 Neurasthenia
- F07.2 Postconcussional syndrome
- E50.0 Vitamin A deficiency with conjunctival xerosis
- E46 Unspecified protein-energy malnutrition
- E05.9 Thyrotoxicosis, unspecified
- T79.4 Traumatic shock
- T81.1 Shock during or resulting from a procedure, not elsewhere classified
- T90.5 Sequelae of intracranial injury
- Z54 Convalescence
- Z73.0 Burn-out
- Z73.2 Lack of relaxation and leisure
- Z73.6 Limitation of activities due to disability
- R63.4 Abnormal weight loss
- G93.1 Anoxic brain damage, not elsewhere classified
- G71.3 Mitochondrial myopathy, not elsewhere classified
- E61.8 Deficiency of other specified nutrient elements
- Z54.8 Convalescence following other treatment